What is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?

Annals of Neurology

Volumn 79, Issue 2, 2016, Pages 204-205

  Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; CORTICOSTEROID;

CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; DISABILITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EMERGENCY CARE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; IMMUNOADSORPTION; MULTICENTER STUDY (TOPIC); MYELITIS; MYELOOPTIC NEUROPATHY; NOTE; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; TREATMENT RESPONSE; FEMALE; MALE; NEUROMYELITIS OPTICA; REGISTER; STATISTICS AND NUMERICAL DATA;

FEMALE; HUMANS; MALE; NEUROMYELITIS OPTICA; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES;

EID: 84958107544     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24557     Document Type: Note

References (15)

1. Wingerchuk DM, Banwell B, Bennett JL, et al., International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.
2. Kimbrough DJ, Fujihara K, Jacob A, et al.,; GJCF-CC&BR. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012; 1: 180-187.
3. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG,. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114.
4. Kitley J, Leite MI, Nakashima I, et al., Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135: 1834-1849.
5. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG,. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007; 68: 603-605.
6. Dau P, Johnson K, Panitch H, Bornstein M,. Plasmapheresis in multiple sclerosis: preliminary findings. Neurology 1980; 30: 1023-1028.
7. Weinshenker B,. Therapeutic plasma exchange for multiple sclerosis. In:, Rudick R, Goodkin D, eds. Multiple Sclerosis: Experimental and Applied Therapeutics. London: Martin Dunitz; 1999: 323-333.
8. Weinshenker BG, O'Brien PC, Petterson TM, et al., A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.
9. Weinshenker BG, Keegan BM, Winters JL, Nakashima I, Fujihara K,. Plasma exchange treatment for CNS inflammatory demyelinating disease. In:, Cohen JA, Rudick RA, eds. Multiple Sclerosis Therapeutics, 4th ed. New York: Cambridge University Press; 2011: 454-464.
10. Watanabe S, Nakashima I, Misu T, et al., Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13: 128-132.
11. Lim YM, Pyun SY, Kang BH, Kim J, Kim KK,. Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler 2013; 19: 1216-1218.
12. Bonnan M, Valentino R, Olindo S, et al., Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009; 15: 487-492.
13. Abboud H, Petrak A, Mealy M, et al., Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler 2015 Apr 28. pii: 1352458515581438. [Epub ahead of print]
14. Kleiter I, Gahlen A, Borisow N, et al.,; on behalf of NEMOS (Neuromyelitis Optica Study Group). Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol. 2015 Nov 4. doi: 10.1002/ana.24554. [Epub ahead of print]
15. Tradtrantip L, Ratelade J, Zhang H, Verkman AS,. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 2013; 73: 77-85.